[Transcatheter arterial chemoembolization for postoperative recurrent hepatocellular carcinoma: therapeutic results in correlation with radiologic findings and treatment methods].
From January 1985 to June 1993, 61 patients with postoperative recurrent hepatocellular carcinoma (HCC) underwent transcatheter arterial chemoembolization (TACE) with Cis-Diammine dichloroplatinum-in-Lipiodol suspension (CLS) and/or Adriamycin-in-Lipiodol suspension (ALS). The effectiveness of TACE was retrospectively analyzed in relation to the presence of distant metastasis and portal vein involvement, and to the number and largest size of tumors which were evaluated by variable imaging modalities including US, CT, MR and hepatic angiography. Cumulative survival rates were calculated from the onset of TACE according to the Kaplan-Meier method. Cumulative survival rate of all cases after TACE was 69% for 1 year, 41% for 2 years, 21% for 3 years, 17% for 4 years and 8% for 5 years, respectively. Significant differences (P < 0.05) in survival rates were seen between the presence and absence of distant metastasis or portal vein involvement. In 52 patients without distant metastasis and/or portal vein involvement, there were significant differences (P < 0.05) in survival rates between single and multiple lesions, and between small (< or = 2.0cm) and large (> 5cm) lesions. In 48 patients, excluding the cases with distant metastasis, and/or portal vein involvement, and more than 5 cm in diameter, there were also significant differences (P < 0.05) in survival rates between combined therapy (CLS+ALS) and others, between CLS and ALS, and between once and multiple courses of TACE.